TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06362668
Drug: Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
Normalized name: bumetanide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
Study: NCT05866562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
Study: NCT04659863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Study: NCT06244316
Drug: rhNGF concentration 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Study: NCT06244316
Drug: rhNGF concentration 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Study: NCT04950114
Drug: GFB-887
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFB-887 is a potent, small molecule inhibitor of TRPC5.
Study: NCT05609812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06564909
Drug: The standard care for the management of myocardial infarction post PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study: NCT05657691
Drug: Xanamem™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
Study: NCT05657691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
Study: NCT01244607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single i.v. administration
Study: NCT05435547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will take Placebo pre-operatively
Study: NCT06339203
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mL
Study: NCT05559931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion over 6 hours
Study: NCT05528926
Drug: Treatment As Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TAU group receives non-pharmacological and pharmacological therapies as usually provided in the participating centres but without having had a structured parent program in the last 6 months assessed at baseline, M1 and M3.
Study: NCT00002398
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06305754
Drug: Acetaminophen (or equivalent)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as rescue medication per approved product label
Study: NCT05628961
Drug: HOPO 14-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
Study: NCT06192589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally twice daily for 28 days in Part 1
Study: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose
Study: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose
Study: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose
Study: NCT05031871
Drug: HR17031 injection ；INS068 injection；SHR20004 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: (INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
Study: NCT05445167
Drug: KLH-2109
Normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05445167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06173895
Drug: LY3454738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT05938179
Drug: Placebo for HS-10353 30mg capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for HS-10353 30mg capsules
Study: NCT05938179
Drug: Placebo for HS-10353 50mg capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for HS-10353 50mg capsules
Study: NCT06168383
Drug: HSK31679 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
Study: NCT06168383
Drug: HSK31679 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
Study: NCT06168383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral administration of placebo from Day 1 to Week 52.
Study: NCT05103397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group.Group (C) (25 patients) patients will receive placebo in form of normal saline
Study: NCT05366179
Drug: CAR.B7-H3T cells infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2).
Study: NCT05274659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05303272
Drug: Mycophenolate Mofetil 500Mg Tab
Normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF will be administered at a starting dose of 1000 milligrams (mg) Q12H and the dose will be tapered to achieve a goal of 0.5-1.0 gram (gm) Q12H. Combined with standard of care prednisone 10-40mg qd through 52 weeks.
Study: NCT05136456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablets taken once daily (QD) for 24 weeks
Study: NCT05841901
Drug: Huang-long Zhi-xiao Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group was given Huang-long Zhi-xiao Granule.1 dose per day, oral in 2 divided doses, 1 course every 4 weeks, for a total of 8 weeks of treatment.
Study: NCT05841901
Drug: Huang-long Zhi-xiao Granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The toncral group was given placebo Huang-long Zhi-xiao Granule.The course of treatment was the same as that of the experimental group.
Study: NCT03602898
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03602898
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05068206
Drug: AK105 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK105 is programmed death 1（PD-1） monoclonal antibody
Study: NCT05068206
Drug: CapeOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapeOX is Capecitabine+Oxaliplatin. Capecitabine is a kind of fluorouracil drug, and Oxaliplatin is a kind of platinum anticancer drug.
Study: NCT05683470
Drug: RBS2418
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBS2418 will be administered orally at 200 mg two times per day (BID).
Study: NCT06009900
Drug: Non-steroidal drug (Celecoxib) group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.
Study: NCT05572190
Drug: ETR028, ETR029, [ETR028 + ETR029] or HCBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone prodrugs
Study: NCT05144984
Drug: NNC0480-0389
Approvals — FDA: no, EMA: no, PMDA: no
Description: A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
Study: NCT05144984
Drug: Placebo (NNC080-0389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
Study: NCT05144984
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
Study: NCT06020495
Drug: Standard hyponatremia treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic
Study: NCT05418010
Drug: Tysabri Injectable Product
Normalized name: Tysabri Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
Study: NCT05418010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
Study: NCT05970497
Drug: KEYTRUDA ®( Pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (PD-1 immune checkpoint inhibitor)
Study: NCT05444751
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence.
Study: NCT06172010
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study: NCT05444751
Drug: SA + ESP
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation.
Study: NCT04807478
Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose, frequency and duration is a decision of the Investigator
Study: NCT05402020
Drug: Inhaled corticosteroids (ICS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS)
Study: NCT05402020
Drug: Long-acting β2-agonists (LABA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists (LABA)
Study: NCT04765722
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Study: NCT06463678
Drug: IVIEW-1201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
Study: NCT06463678
Drug: NATACYN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.
Study: NCT04612699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05293509
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 IV-by vein
Study: NCT05293509
Drug: Cyclophosphamide (Cy)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: by vein
Study: NCT04905654
Drug: Levcromakalim
Approvals — FDA: no, EMA: no, PMDA: no
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT06364423
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Study: NCT04457089
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
Study: NCT06340958
Drug: CLE-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of CLE-100 administered once daily
Study: NCT06340958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo administered once daily
Study: NCT06417320
Drug: ACEI, SGLT-2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)
Study: NCT04991103
Drug: DaraVRD
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22).
Study: NCT05423249
Drug: Ascorbic Acid 500Mg Tab
Normalized name: ASCORBIC ACID 500MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ascorbic acid 500 mg daily, to improve absorption of oral iron
Study: NCT05423249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo pill once daily
Study: NCT06388187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT04950075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06349408
Drug: IBI3001
Approvals — FDA: no, EMA: no, PMDA: no
Description: The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)
Study: NCT06779136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
Study: NCT06246396
Drug: Minocycline Hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline Hydrochloride 100 mg twice daily
Study: NCT06246396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04649242
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 75 mg or 50 mg ODT placebo
Study: NCT06210477
Drug: medical treatment for lower urinary tract symptoms
Approvals — FDA: no, EMA: no, PMDA: no
Description: The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
Study: NCT06351306
Drug: DecitabineCedazuridine (Inqovi ®)
Normalized name: Inqovi
DrugBank: Cedazuridine (DB15694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg decitabine and 100 mg cedazuridine oral tablet
Study: NCT04669899
Drug: JTX-8064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05827653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a week, for 28 days
Study: NCT04855799
Drug: Aquamin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Study: NCT06686615
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No drug was administered in this observational study.
Study: NCT06461039
Drug: NNC0487-0111 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0487-0111 A will be administered subcutaneously.
Study: NCT06461039
Drug: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg (Oral contraceptive OC) will be taken orally.
Study: NCT06461039
Drug: Acetaminophen - 500 mg/15 ml
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen - 500 mg/15 ml will be taken orally.
Study: NCT05592626
Drug: STAR0602
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, intravenous infusion
Study: NCT04983043
Drug: QiShen YiQi Dripping Pills placebo 3 bags
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT05314374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks exactly like the study drug, but it contains no active ingredient. 1000mg tablets orally twice a daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 4 days.
Study: NCT04882683
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg per kilogram per day for three months
Study: NCT06198764
Drug: Coly Mycin M Injectable Product
Normalized name: Coly Mycin M Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coly Mycin M is the originally marketed colistimethate sodium for injection.
Study: NCT05892770
Drug: Zinc gluconate supplement
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
Study: NCT04457596
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04698057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
Study: NCT06034743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Study: NCT06544733
Drug: Placebo to Match BVY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06544733
Drug: GS-1720/GS-4182 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT06544733
Drug: Placebo to Match GS1720/GS-4182 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT05799521
Drug: Optate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline Buffer
Study: NCT05799521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT05029635
Drug: HMPL-523
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523 will be oral administrated once daily for 24 weeks